KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Gsk (GSK) Net Income - Minority (2016 - 2026)

Gsk has reported Net Income - Minority over the past 18 years, most recently at -$24.1 billion for Q1 2026.

  • For Q1 2026, Net Income - Minority fell 34.98% year-over-year to -$24.1 billion; the TTM value through Mar 2026 reached -$24.1 billion, down 34.98%, while the annual FY2025 figure was -$21.8 billion, 24.15% down from the prior year.
  • Net Income - Minority for Q1 2026 was -$24.1 billion at Gsk, down from -$21.8 billion in the prior quarter.
  • Over five years, Net Income - Minority peaked at -$10.8 billion in Q3 2022 and troughed at -$24.1 billion in Q1 2026.
  • A 5-year average of -$18.1 billion and a median of -$18.0 billion in 2024 define the central range for Net Income - Minority.
  • Biggest five-year swings in Net Income - Minority: skyrocketed 49.28% in 2022 and later plummeted 34.98% in 2026.
  • Year by year, Net Income - Minority stood at -$12.4 billion in 2022, then plummeted by 33.26% to -$16.6 billion in 2023, then dropped by 5.92% to -$17.5 billion in 2024, then decreased by 24.15% to -$21.8 billion in 2025, then fell by 10.48% to -$24.1 billion in 2026.
  • Business Quant data shows Net Income - Minority for GSK at -$24.1 billion in Q1 2026, -$21.8 billion in Q4 2025, and -$21.8 billion in Q3 2025.